1st Quarter - Report

BROWN RUDNICK LLP for APOTEX CORPORATION

Period 1st Quarter 2018 Filed Apr 18, 2018 Signed by Henry W. Menn III

Official filing
Firm
BROWN RUDNICK LLP
Client
APOTEX CORPORATION
Income
$50,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Issues relating to the USPTO inter partes review proceeding.

LobbyistCovered position, as disclosed
HENRY W MENN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S. 2476-Expanding Access to Low Cost Generic Drugs Act.

LobbyistCovered position, as disclosed
HENRY W MENN CoS, Sen. Bob Graham (01 - 04); Min SD & Counsel, Cmte on Vet Affairs (04); Sp Asst Leg Aff, FDA Off of Commission (93-95)

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2476 (115th), H.R. 2212 (115th), S. 974 (115th), H.R. 2051 (115th)

Medicare/Medicaid MMM

P.L. 114-74 section 602 relating to Medicaid additional rebate for generic drugs.

LobbyistCovered position, as disclosed
HENRY W MENN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

H.R. 1892-The Bipartisan Budget Act of 2018 & H.R. 1625-Consolidated Appropriations Act of 2018 relating to REMS reform.

LobbyistCovered position, as disclosed
HENRY W MENN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1625 (115th), H.R. 1892 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.